PMID- 31595715
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20211204
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 8
IP  - 17
DP  - 2019 Dec
TI  - Treatment patterns, adverse events, healthcare resource use and costs among 
      commercially insured patients with mantle cell lymphoma in the United States.
PG  - 7174-7185
LID - 10.1002/cam4.2559 [doi]
AB  - INTRODUCTION: There are limited data on treatment patterns, adverse events (AEs), 
      and economic burden in younger, commercially insured patients treated for mantle 
      cell lymphoma (MCL). METHODS: Adults with >/=1 treatment for MCL between 1 November 
      2013-31 December 2017 were identified from IQVIA Real-World Data Adjudicated 
      Claims-US; index date was first treatment. Patients carried >/=1 MCL diagnosis, 
      were newly treated, and were enrolled continuously for >/=12 months prior to and 
      >/=30 days following index. Patients receiving the four most common MCL regimens 
      were included. Measures included frequency of incident AEs, resource use, and 
      costs overall and by number of AEs. Adjusted logistic regression and generalized 
      linear modeling evaluated risk of hospitalization and all-cause costs per patient 
      per month (PPPM). RESULTS: Two thousand five hundred and nine treated patients 
      had a drug-specific code and were classified to a specific treatment regimen. Of 
      those patients, 1785 patients received at least one of the four most commonly 
      used MCL regimens (R-CHOP, rituximab monotherapy, B-R, and ibrutinib) at some 
      point over follow-up (median 23 months). R-CHOP was the most common regimen 
      observed in the first line (26%), followed by rituximab monotherapy (19%), B-R 
      (15%), and ibrutinib (5%). The median age was 57 years; median Charlson 
      Comorbidity Index was 0. Among patients receiving the four most common regimens, 
      63% of patients experienced >/=1 incident AE (R-CHOP 77%, B-R 58%, and ibrutinib 
      52%). An increasing number of incident AEs was associated with increased 
      hospitalization risk (odds ratio = 2.4; 95% Confidence Interval [CI] 2.1-2.7) and 
      increased mean costs PPPM (cost ratio = 1.1; 95% CI 1.1-1.2). DISCUSSION: This is 
      the largest study describing treatment patterns and clinical and economic impact 
      of MCL treatment. The most common regimens were R-CHOP, rituximab monotherapy, 
      B-R, and ibrutinib. The majority of treated patients experienced at least one 
      incident AE, with hospitalization risk and all-cause costs increasing as the 
      number of AEs increased.
CI  - (c) 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Kabadi, Shaum M
AU  - Kabadi SM
AD  - AstraZeneca, Gaithersburg, MD, USA.
FAU - Near, Aimee
AU  - Near A
AD  - IQVIA, Falls Church, VA, USA.
FAU - Wada, Keiko
AU  - Wada K
AD  - IQVIA, Falls Church, VA, USA.
FAU - Burudpakdee, Chakkarin
AU  - Burudpakdee C
AD  - IQVIA, Falls Church, VA, USA.
LA  - eng
GR  - AstraZeneca/International
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20191008
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Piperidines)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyrimidines)
RN  - 0 (R-CHOP protocol)
RN  - 1X70OSD4VX (ibrutinib)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - JAC85A2161 (Adenine)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adenine/analogs & derivatives
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse 
      effects/economics
MH  - *Cost of Illness
MH  - Cyclophosphamide/administration & dosage/adverse effects/economics
MH  - Doxorubicin/administration & dosage/adverse effects/economics
MH  - Drug-Related Side Effects and Adverse Reactions/*economics/epidemiology/etiology
MH  - Female
MH  - Follow-Up Studies
MH  - Health Care Costs/*statistics & numerical data
MH  - Health Care Rationing/economics/statistics & numerical data
MH  - Hospitalization/economics/statistics & numerical data
MH  - Humans
MH  - Incidence
MH  - Insurance, Health/economics/statistics & numerical data
MH  - Lymphoma, Mantle-Cell/*drug therapy/economics
MH  - Male
MH  - Middle Aged
MH  - Piperidines
MH  - Practice Patterns, Physicians'/economics/statistics & numerical data
MH  - Prednisone/administration & dosage/adverse effects/economics
MH  - Pyrazoles/administration & dosage/adverse effects/economics
MH  - Pyrimidines/administration & dosage/adverse effects/economics
MH  - Retrospective Studies
MH  - Rituximab/administration & dosage/adverse effects/economics
MH  - Treatment Outcome
MH  - United States/epidemiology
MH  - Vincristine/administration & dosage/adverse effects/economics
MH  - Young Adult
PMC - PMC6885896
OTO - NOTNLM
OT  - Mantle cell lymphoma
OT  - adverse events
OT  - costs
OT  - healthcare resource use
OT  - real world
OT  - treatment patterns
EDAT- 2019/10/09 06:00
MHDA- 2020/09/25 06:00
PMCR- 2019/10/08
CRDT- 2019/10/10 06:00
PHST- 2018/11/15 00:00 [received]
PHST- 2019/08/26 00:00 [revised]
PHST- 2019/09/03 00:00 [accepted]
PHST- 2019/10/09 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
PHST- 2019/10/10 06:00 [entrez]
PHST- 2019/10/08 00:00 [pmc-release]
AID - CAM42559 [pii]
AID - 10.1002/cam4.2559 [doi]
PST - ppublish
SO  - Cancer Med. 2019 Dec;8(17):7174-7185. doi: 10.1002/cam4.2559. Epub 2019 Oct 8.